SingleTimeMicroneedles

Jasdeep Singh, CEO
jasdeep.singh@stmpatch.com
860-847-0138
https://stmpatch.com

Overview
SingleTimeMicroneedles’s mission is to democratize access to lifesaving veterinary and human pharmaceuticals.
STM has created a patented, painless, removable, transdermal microneedle patch that can deliver vaccines and therapeutics
cheaper, quicker, and more effectively in humans and animals. STM’s delivery technology is the only platform engineered to deliver
single- or multi-dose medications in one application without needles or other equipment. With vaccines, by eliminating pain,
refrigerated supply chains, and the need for specially trained health care personnel, STM’s patch will reduce costs, improve
patient access, enhance prophylactic outcomes, reduce personnel burdens, and resolve supply chain challenges.
TeamSTM founders balance leadership in science and strategy:● Thanh Duc Nguyen, Ph.D. – Dr. Nguyen is an associate professor of mechanical engineering at the University of Connecticut
who is an innovator, nine-time patent holder, and research leader who has raised over $5M in grant and private funding.
Thanh founded two start-up companies and has an extensive pharmaceutical and private industry network.
● Jasdeep Singh, Ed.D., MBA – Dr. Singh has managed a variety of organizations, led a $500K seed round at a $3M valuation,and led schools with over 150 employees and multimillion dollar budgets. Jasdeep has also been a team leader innumerous negotiations, closed an international licensing agreement, and brings consulting experience and a VC and angel
investor network.

ProductSTM’s core technology is a self-administered patch that can be painlessly applied on the skin toembed arrays of microneedles (MNs). Minutes after administration, the patch is removed andMNs are imperceptibly embedded in the superficial skin layer. The MNs are composed of abiodegradable polymer, such as those used in surgical sutures, and are engineered to releasevaccines immediately, repeatedly, or over a period of time – all in a single application. This
technology supports multiple types of vaccines and therapeutics, including subunit
protein-based antigens, vector-based vaccines, mRNAs, or any compound that benefits frommultiple or longitudinal dosing. Due to our construction, vaccines are stabilized against hightemperatures, thus avoiding the need for a refrigerated supply chain and affirming theantigenicity while remaining in the skin. STM are being planned for medications, animalapplications, and certain compounds in the nutraceutical market.

Revenue Model
STM will create multiple revenue streams through manufacturing, licensing, and contract research, depending on the pharma
agent. With STM’s ability to create cost savings of up to 40% throughout the medical supply chain, we are able to meet the needsof pharma companies, distributors, and doctors due to lowering research, inventory, transportation, application, and deployment
costs. The STM patch is also vaccine-, drug-, and company-agnostic, allowing STM to either develop in-house products (such aswith generic drugs) or work with a drug developer on a profitable licensing model for a variety of their products (such as vaccines).

Market Opportunity
Vaccines
The North American vaccine market is estimated to be $16-35B with CAGRs ranging from 5.9-12.6%. We anticipate entering themarket by targeting high frequency vaccines, such as influenza or pneumococcal, and rarer illnesses that require long inventory
storage to prepare for quick deployment.
As an example, STM could provide unique value in flu vaccine deployment due to our ability to release multiple doses over time,
as compared to current single-injection administration. Research has shown multiple doses of the same influenza vaccine canincrease effectiveness, especially in children. The influenza vaccine is the most utilized vaccine in the U.S.: there were 193.8M
doses of the influenza vaccine delivered in the U.S. in 2020-2021 with a value of nearly $3B and a CAGR of 16.9%. Within that
opportunity, our SAM would include groups required to receive the vaccine as part of the occupation or schooling.

Animal Applications
The global animal vaccine market is estimated to be $11.8B with a CAGR of 9.3%. We anticipate entering the market by targetinghigh value animals that require multiple multi-dose vaccines per year, such as cattle and certain companion animals. We are also
testing drug candidates, each with a large market opportunity, that require multiple doses over many years, such asanti-parasitics.
Competition
Of all the products under active research or clinical trials within the microneedle market, none has the unique advantage that STM
brings: variable (instant, longitudinal, multiple separate dose) deployment of a pharmaceutical in a single application and mRNA
temperature stabilization. However, there are additional players investigating MN technology for use in vaccines. Largely, thesepotential competitors fall into 3 categories: pharmaceutical companies, contract manufacturers, and academic institutions.

STM’s Microneedles Are More Effective Than Injections